Form D · Pharmaceuticals
Compound Holdings I, LLC
Chicago, IL · CIK 0001600837
Offering snapshot reported Feb 24, 2014 · SEC filing
- Reported sold
- $412M Offering amount: $412M
- Investors reported
- 178 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 12, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 24, 2014 | Initial | $412,000,000 | No comparison | 178 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-212385
Source: Form D, filed Feb 24, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Adasczik | Executive |
| Nicholas Alexos | Director |
| Matthew Bennett | Executive |
| Elizabeth Betten | Director |
| James Briggs | Executive |
| Scott Charles | Executive |
| Douglas Greene | Executive |
| Matthew Holt | Director |
| Anatasios Konidaris | Executive |
| Jonathan Provoost | Executive |
| Stephen Ross | Executive |
| William Scheinler | Executive |
| Lien Lung Sheu | Executive |
| Jason Shideler | Director |
| Joseph Stauffer | Executive |
| Timothy Sullivan | Director |
| Daniel Tasse | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Three First National Plaza Suite 4600
Chicago, IL, 60602
Chicago, IL, 60602